Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Vollmar, A M
MetadataShow full item record
AbstractTargeting the actin cytoskeleton (CSK) of cancer cells offers a valuable strategy in cancer therapy. There are a number of natural compounds that interfere with the actin CSK, but the mode of their cytotoxic action and, moreover, their tumor-specific mechanisms are quite elusive. We used the myxobacterial compound Chondramide as a tool to first elucidate the mechanisms of cytotoxicity of actin targeting in breast cancer cells (MCF7, MDA-MB-231). Chondramide inhibits cellular actin filament dynamics shown by a fluorescence-based analysis (fluorescence recovery after photobleaching (FRAP)) and leads to apoptosis characterized by phosphatidylserine exposure, release of cytochrome C from mitochondria and finally activation of caspases. Chondramide enhances the occurrence of mitochondrial permeability transition (MPT) by affecting known MPT modulators: Hexokinase II bound to the voltage-dependent anion channel (VDAC) translocated from the outer mitochondrial membrane to the cytosol and the proapoptotic protein Bad were recruited to the mitochondria. Importantly, protein kinase C-ɛ (PKCɛ), a prosurvival kinase possessing an actin-binding site and known to regulate the hexokinase/VDAC interaction as well as Bad phosphorylation was identified as the link between actin CSK and apoptosis induction. PKCɛ, which was found overexpressed in breast cancer cells, accumulated in actin bundles induced by Chondramide and lost its activity. Our second goal was to characterize the potential tumor-specific action of actin-binding agents. As the nontumor breast epithelial cell line MCF-10A in fact shows resistance to Chondramide-induced apoptosis and notably express low level of PKCɛ, we suggest that trapping PKCɛ via Chondramide-induced actin hyperpolymerization displays tumor cell specificity. Our work provides a link between targeting the ubiquitously occurring actin CSK and selective inhibition of pro-tumorigenic PKCɛ, thus setting the stage for actin-stabilizing agents as innovative cancer drugs. This is moreover supported by the in vivo efficacy of Chondramide triggered by abrogation of PKCɛ signaling shown in a xenograft breast cancer model.
CitationTargeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ. 2014, 5:e1398 Cell Death Dis
JournalCell death & disease
The following license files are associated with this item:
- In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
- Authors: Menhofer MH, Bartel D, Liebl J, Kubisch R, Busse J, Wagner E, Müller R, Vollmar AM, Zahler S
- Issue date: 2014 Nov 1
- The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility.
- Authors: Menhofer MH, Kubisch R, Schreiner L, Zorn M, Foerster F, Mueller R, Raedler JO, Wagner E, Vollmar AM, Zahler S
- Issue date: 2014
- The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption.
- Authors: Lee MW, Bassiouni R, Sparrow NA, Iketani A, Boohaker RJ, Moskowitz C, Vishnubhotla P, Khaled AS, Oyer J, Copik A, Fernandez-Valle C, Perez JM, Khaled AR
- Issue date: 2014 May 22
- Pharmacological characterization of actin-binding (-)-doliculide.
- Authors: Foerster F, Braig S, Chen T, Altmann KH, Vollmar AM
- Issue date: 2014 Sep 15
- Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism.
- Authors: Shulga N, Wilson-Smith R, Pastorino JG
- Issue date: 2009 Oct 15